EA-114
Hormone-receptor-positive (HR+) metastatic breast cancer
Pre-NDAPlans to file NDA in 2024
Key Facts
Indication
Hormone-receptor-positive (HR+) metastatic breast cancer
Phase
Pre-NDA
Status
Plans to file NDA in 2024
Company
About Eagle Pharmaceuticals
Eagle Pharmaceuticals is a NASDAQ-listed company (EGRX) headquartered in Woodcliff Lake, NJ, dedicated to developing innovative drugs that result in meaningful improvements in patients' lives. The company operates with a strategic focus on critical care and oncology, balancing a commercial-stage portfolio with a pipeline of novel product candidates. Eagle's mission is to bring brilliant science to life by serving patients, healthcare providers, and health systems, thereby creating value for all stakeholders.
View full company profile